PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hairfollicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.
TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hairfollicle stem cells and may maintain gains without immediate loss, unlike minoxidil.
The conversation is about whether treatments like finasteride, dutasteride, and minoxidil can make single hairfollicles produce multiple hairs again. The user is curious if these medications can thicken hair and prolong the growth phase.
KPV, a peptide patented by L'Oreal, may promote hair growth and reduce hair loss by extending the anagenphase and has anti-inflammatory properties. It could be combined with treatments like minoxidil for enhanced effects.
PP405 may damage hairfollicles if used long-term, suggesting cycling might be necessary. Combining it with finasteride could help maintain hair growth.